APGE - CIK 0001974640
Apogee Therapeutics, Inc. trades as APGE and has a market capitalization of $6.13 B, making it the #1248 largest US-listed company by market value. This page tracks Apogee Therapeutics, Inc. through 262 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-27 |
| Major company event | 8-K | 2026-05-27 |
| Insider trade | 4 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Insider trade | 4 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-06 |
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart | Apogee Therapeutics, Inc.
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis | Apogee Therapeutics, Inc.
Webcast to be held Wednesday, May 27th at 8:00 a.m. ET
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results | Apogee Therapeutics, Inc.
The largest companies sharing Apogee Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Apogee Therapeutics, Inc. (APGE) has a market capitalization of $6.13 B as of 2026-06-10, ranking #1248 among US-listed companies.
In its latest fiscal year Apogee Therapeutics, Inc. reported a net loss of $255.84M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million | Apogee Therapeutics, Inc.